Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.26
OTCPK:IGXT's Cash-to-Debt is ranked lower than
78% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. OTCPK:IGXT: 1.26 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:IGXT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: N/A Max: No Debt
Current: 1.26
Equity-to-Asset 0.43
OTCPK:IGXT's Equity-to-Asset is ranked lower than
76% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OTCPK:IGXT: 0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:IGXT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.4  Med: 0.62 Max: 0.9
Current: 0.43
-0.4
0.9
Piotroski F-Score: 4
Altman Z-Score: 3.74
Beneish M-Score: -4.29
WACC vs ROIC
12.10%
-16.84%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -12.72
OTCPK:IGXT's Operating Margin % is ranked higher than
65% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. OTCPK:IGXT: -12.72 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:IGXT' s Operating Margin % Range Over the Past 10 Years
Min: -555.91  Med: -140.55 Max: 27.2
Current: -12.72
-555.91
27.2
Net Margin % -16.44
OTCPK:IGXT's Net Margin % is ranked higher than
63% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. OTCPK:IGXT: -16.44 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:IGXT' s Net Margin % Range Over the Past 10 Years
Min: -557.27  Med: -162.29 Max: 25.34
Current: -16.44
-557.27
25.34
ROE % -19.84
OTCPK:IGXT's ROE % is ranked higher than
62% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. OTCPK:IGXT: -19.84 )
Ranked among companies with meaningful ROE % only.
OTCPK:IGXT' s ROE % Range Over the Past 10 Years
Min: -1461.46  Med: -82.57 Max: 25.47
Current: -19.84
-1461.46
25.47
ROA % -8.69
OTCPK:IGXT's ROA % is ranked higher than
68% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. OTCPK:IGXT: -8.69 )
Ranked among companies with meaningful ROA % only.
OTCPK:IGXT' s ROA % Range Over the Past 10 Years
Min: -193.99  Med: -64.12 Max: 16.99
Current: -8.69
-193.99
16.99
ROC (Joel Greenblatt) % -12.96
OTCPK:IGXT's ROC (Joel Greenblatt) % is ranked higher than
72% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. OTCPK:IGXT: -12.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:IGXT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -808.25  Med: -259.09 Max: 54.17
Current: -12.96
-808.25
54.17
3-Year Revenue Growth Rate 65.80
OTCPK:IGXT's 3-Year Revenue Growth Rate is ranked higher than
91% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. OTCPK:IGXT: 65.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:IGXT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -9.9 Max: 192.4
Current: 65.8
0
192.4
3-Year EBITDA Growth Rate -37.70
OTCPK:IGXT's 3-Year EBITDA Growth Rate is ranked lower than
88% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. OTCPK:IGXT: -37.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:IGXT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -12.25 Max: 129.6
Current: -37.7
0
129.6
3-Year EPS without NRI Growth Rate -12.60
OTCPK:IGXT's 3-Year EPS without NRI Growth Rate is ranked lower than
64% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. OTCPK:IGXT: -12.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:IGXT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -14.15 Max: 141
Current: -12.6
0
141
GuruFocus has detected 6 Warning Signs with Intelgenx Technologies Corp $OTCPK:IGXT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:IGXT's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with OTCPK:IGXT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:XENE, TSX:ONC, NAS:SRRA, TSX:NEPT, XCNQ:TBP, TSX:HBP, TSXV:CZO, TSXV:EMH, TSX:TRIL, TSX:IPCI, XCNQ:VGW, XCNQ:PBT.U, TSX:BU, TSXV:MDNA, TSX:CXR, TSXV:COV, XCNQ:CRZ, XCNQ:THC, TSXV:IPA, TSX:APS » details
Traded in other countries:IGX.Canada, 0IL.Germany,
Headquarter Location:Canada
Intelgenx Technologies Corp is a drug delivery company. The Company is engaged in the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.

Intelgenx Technologies Corp., was incorporated in Delaware on July 27, 1999. The Company is a drug delivery company. It is engaged in the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies. Its product development efforts are based upon three platform technologies: Versafilm- an oral film technology, VersaTab- a multilayer tablet technology and AdVersa- a mucoadhesive tablet technology. The Oral Film technology consists of a thin (25-35 micron) polymeric film comprised of United States Pharmacopeia (USP) components that are approved by the FDA for use in food, pharmaceutical, and cosmetic products. Its multilayer tablet technology allows for the development of oral controlled-release products. The mucoadhesive tablet is a drug delivery system capable of adhering to the oral mucosa and releasing the drug onto the site of application at a controlled rate. The Company's product portfolio includes a blend of generic and branded products based on its proprietary delivery technology. Some of its products are INT0001/2004, INT0004/2006, INT0007/2006, and among others. The Company competes with pharmaceutical industries. Some of its competitors include Monosol Rx, Tesa-Labtec GmbH, BioDelivery Sciences International, Inc and LTS Lohmann Therapy Systems Corp. It is subject to change in governmental regulations, healthcare legislations, availability of financing, patent litigation and other factors.

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 84.00
IGXT's Price-to-Owner-Earnings is ranked lower than
86% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. IGXT: 84.00 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
IGXT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 26.36  Med: 74.5 Max: 293.33
Current: 84
26.36
293.33
PB Ratio 11.07
IGXT's PB Ratio is ranked lower than
87% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. IGXT: 11.07 )
Ranked among companies with meaningful PB Ratio only.
IGXT' s PB Ratio Range Over the Past 10 Years
Min: 4.66  Med: 10.13 Max: 90
Current: 11.07
4.66
90
PS Ratio 9.66
IGXT's PS Ratio is ranked higher than
53% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. IGXT: 9.66 )
Ranked among companies with meaningful PS Ratio only.
IGXT' s PS Ratio Range Over the Past 10 Years
Min: 5  Med: 15.29 Max: 97.14
Current: 9.66
5
97.14
Price-to-Operating-Cash-Flow 31.11
IGXT's Price-to-Operating-Cash-Flow is ranked lower than
67% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. IGXT: 31.11 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
IGXT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 14.87  Med: 38.85 Max: 58.89
Current: 31.11
14.87
58.89
EV-to-EBIT -74.35
IGXT's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. IGXT: -74.35 )
Ranked among companies with meaningful EV-to-EBIT only.
IGXT' s EV-to-EBIT Range Over the Past 10 Years
Min: -86.06  Med: -13.1 Max: 375.1
Current: -74.35
-86.06
375.1
EV-to-EBITDA -408.86
IGXT's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. IGXT: -408.86 )
Ranked among companies with meaningful EV-to-EBITDA only.
IGXT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -473.32  Med: -13.6 Max: 116.6
Current: -408.86
-473.32
116.6
Current Ratio 1.22
IGXT's Current Ratio is ranked lower than
85% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. IGXT: 1.22 )
Ranked among companies with meaningful Current Ratio only.
IGXT' s Current Ratio Range Over the Past 10 Years
Min: 0.66  Med: 3.97 Max: 11.6
Current: 1.22
0.66
11.6
Quick Ratio 1.22
IGXT's Quick Ratio is ranked lower than
82% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. IGXT: 1.22 )
Ranked among companies with meaningful Quick Ratio only.
IGXT' s Quick Ratio Range Over the Past 10 Years
Min: 0.66  Med: 3.97 Max: 11.6
Current: 1.22
0.66
11.6
Days Sales Outstanding 27.15
IGXT's Days Sales Outstanding is ranked higher than
81% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. IGXT: 27.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
IGXT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.15  Med: 130.94 Max: 390.59
Current: 27.15
27.15
390.59

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.10
IGXT's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. IGXT: -2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IGXT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -120.3  Med: -23.8 Max: -2.1
Current: -2.1
-120.3
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 10.50
IGXT's Price-to-Tangible-Book is ranked lower than
81% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. IGXT: 10.50 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
IGXT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.25  Med: 10 Max: 75
Current: 10.5
5.25
75
Price-to-Median-PS-Value 0.63
IGXT's Price-to-Median-PS-Value is ranked higher than
67% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. IGXT: 0.63 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IGXT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.39  Med: 1 Max: 5.64
Current: 0.63
0.39
5.64
Earnings Yield (Greenblatt) % -1.36
IGXT's Earnings Yield (Greenblatt) % is ranked higher than
70% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. IGXT: -1.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IGXT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -39  Med: -6 Max: 5.3
Current: -1.36
-39
5.3

More Statistics

Revenue (TTM) (Mil) $5.76
EPS (TTM) $ -0.02
Beta1.79
Short Percentage of Float0.00%
52-Week Range $0.48 - 1.09
Shares Outstanding (Mil)65.42

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 7 8 17
EPS ($) -0.02 -0.05 0.04
EPS without NRI ($) -0.02 -0.05 0.04
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OTCPK:IGXT

Headlines

Articles On GuruFocus.com
RedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT® for Migraines in Luxembo Apr 13 2017 
IntelGenx and RedHill Biopharma Announce Signing of Definitive Agreement for Commercialization of RI Jul 05 2016 
IntelGenx Reports Amendment of Stock Option Plan May 12 2016 
IntelGenx Reports First Quarter 2016 Financial Results May 10 2016 
IntelGenx to Report First Quarter 2016 Financial Results on May 10, 2016 May 05 2016 
IntelGenx and RedHill Biopharma Announce RIZAPORT(TM) Commercialization Term Sheet With Grupo Juste Mar 29 2016 
IntelGenx Announces Development and Commercialization Term Sheet with a Global Pharmaceutical Compan Mar 24 2016 
IntelGenx to Host Conference Call and Webcast of Fourth Quarter and Full-Year 2015 Financial Results Mar 09 2016 
IntelGenx Appoints Dr. Dana Matzen as Vice President, Business Development Mar 02 2016 
IntelGenx Announces USPTO Has Granted Patent Protecting RIZAPORT(TM) Oral Film for Migraines Feb 18 2016 

More From Other Websites
IntelGenx Presents at BIT's 7th Annual International Symposium of Drug Delivery Systems Jul 12 2017
IntelGenx Completes CDN$6.8 Million Convertible Debenture Offering Jul 12 2017
IntelGenx Files Final Short Form Prospectus In Connection With Offering of Convertible Unsecured... Jun 29 2017
IntelGenx Receives USPTO Notice of Allowance for Oral Film Dosage Form Technology Patent Jun 27 2017
IntelGenx Announces Issuance of US Patent for Topical Oral Film Technology Jun 08 2017
IntelGenx Technologies Corp. :IGXT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017 May 26 2017
IntelGenx reports 1Q loss May 11 2017
IntelGenx Reports First Quarter 2017 Financial Results May 11 2017
Investor Network: Intelgenx Technologies Corp. to Host Earnings Call May 11 2017
IntelGenx to Report First Quarter 2017 Financial Results on May 11, 2017 - Conference Call to Follow May 04 2017
RedHill Biopharma Reports 2017 First Quarter Financial Results May 03 2017
IntelGenx and RedHill Biopharma Announce Marketing Approval of RIZAPORT(R) for Migraines in... Apr 13 2017
IntelGenx Files Preliminary Short Form Prospectus in Connection With a Proposed Offering of... Apr 05 2017
IntelGenx Presents at the 13th International Conference on Alzheimer's and Parkinson's Diseases Apr 04 2017
IntelGenx and Tetra Bio-Pharma Announce the Signing of a Definitive Agreement for the Development... Apr 03 2017
IntelGenx Technologies Corp. :IGXT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 30, 2017 Mar 30 2017
IntelGenx Reports Fourth Quarter and Full-Year 2016 Financial Results Mar 28 2017
Oral Film Exclusivity Granted to IntelGenx' VersaFilm(TM) for Tadalafil Erectile Dysfunction Dosing... Mar 28 2017
IntelGenx to Report Fourth Quarter and Full Year 2016 Financial Results on March 28, 2017 -... Mar 21 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}